{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T22:31:06Z","timestamp":1769121066332,"version":"3.49.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":2221,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["#16SFRN30180010"],"award-info":[{"award-number":["#16SFRN30180010"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["#16SFRN30180010"],"award-info":[{"award-number":["#16SFRN30180010"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Sodium\u2013glucose co-transporter (SGLT)-2 inhibitors have been shown to reduce the risk of cardiovascular death and heart failure (HF) hospitalization in patients with type 2 diabetes mellitus (DM) and high cardiovascular risk in two large clinical outcome trials: empagliflozin in EMPA-REG OUTCOME and canagliflozin in CANVAS. The scope of eligibility for SGLT-2 inhibitors (empagliflozin and canagliflozin) among patients with type 2 DM and HF, based on clinical trial criteria and current US Food and Drug Administration (FDA) labelling criteria, remains unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Using data from the US Get With The Guidelines (GWTG)\u2014Heart Failure registry, we evaluated the proportion of patients with DM and HF eligible for SGLT-2 inhibitor therapy based on the clinical trial criteria and the US FDA labelling criteria. The GWTG-HF registry is a quality improvement registry of patients admitted in hospital with HF in the USA. We included GWTG-HF registry participants meeting eligibility criteria hospitalized between August 2014 and 30 June 2017 from sites fully participating in the registry. The initial inclusion time point reflects when both drugs had FDA approval. Among the 139 317 patients (out of 407 317) with DM hospitalized with HF (in 460 hospitals; 2014 to 2017), the median age was 71 years, 47% (n = 65 685) were female, and 43% (n = 59 973) had HF with reduced ejection fraction. Overall, 43% (n = 59 943) were eligible for the EMPA-REG OUTCOME trial, 45% (n = 62 818) were eligible for the CANVAS trial, and 34% (n = 47 747) of patients were eligible for either SGLT-2 inhibitors based on the FDA labelling criteria. Among the FDA-eligible patients, 91.5% (n = 43 708) were eligible for either the EMPA-REG OUTCOME trial or the CANVAS trial. Patients who were FDA eligible, compared with those who were not, were younger (70.0 vs. 72.0 years of age), more likely to be male (57.7 vs. 50.3%), and had less burden of co-morbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The majority of patients with DM who are hospitalized with HF are not eligible for SGLT-2 inhibitor therapies. Ongoing studies evaluating the safety and efficacy of SGLT-2 inhibitors among patients with HF may potentially broaden the population that may benefit from these therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.12528","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T11:41:41Z","timestamp":1574250101000},"page":"275-279","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Eligibility of Sodium\u2013glucose Co-Transporter-2 Inhibitors Among Patients with Diabetes Mellitus Admitted for Heart Failure"],"prefix":"10.1093","volume":"7","author":[{"given":"Abhinav","family":"Sharma","sequence":"first","affiliation":[{"name":"Duke Clinical Research Institute, Duke University , 200 Morris Street, Durham, NC, 27701 ,","place":["USA"]},{"name":"Division of Cardiology, McGill University , Montreal, Quebec ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Wu","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University , 200 Morris Street, Durham, NC, 27701 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin A.","family":"Ezekowitz","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Dentistry, Canadian VIGOUR Centre, University of Alberta , Edmonton, Alberta ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary Michael","family":"Felker","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University , 200 Morris Street, Durham, NC, 27701 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob A.","family":"Udell","sequence":"additional","affiliation":[{"name":"Peter Munk Cardiac Centre, University Health Network and Women's College Hospital, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Heidenreich","sequence":"additional","affiliation":[{"name":"Veterans' Affairs Palo Alto Health Care System , Palo Alto, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[{"name":"The Ahmanson\u2014University of California Los Angeles Cardiomyopathy Centre, Ronald Regan University of California Los Angeles Medical Centre , Los Angeles, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth W.","family":"Mahaffey","sequence":"additional","affiliation":[{"name":"Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine , Palo Alto, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian F.","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University , 200 Morris Street, Durham, NC, 27701 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam D.","family":"DeVore","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University , 200 Morris Street, Durham, NC, 27701 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,11,20]]},"reference":[{"key":"2026012115053475900_ehf212528-bib-0001","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004646","article-title":"Trends in non-cardiovascular comorbidities among patients hospitalized with heart failure: insights from the Get With The Guidelines\u2014Heart Failure Registry","volume":"11","author":"Sharma","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026012115053475900_ehf212528-bib-0002","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/ejhf.912","article-title":"A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure","volume":"19","author":"Sharma","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012115053475900_ehf212528-bib-0003","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026012115053475900_ehf212528-bib-0004","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012115053475900_ehf212528-bib-0005","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2337\/dc17-1091","article-title":"Causes of death in a contemporary cohort of patients with type 2 diabetes and atherosclerotic cardiovascular disease: insights from the TECOS trial","volume":"40","author":"Sharma","year":"2017","journal-title":"Diabetes Care"},{"key":"2026012115053475900_ehf212528-bib-0006","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/ejhf.633","article-title":"Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes","volume":"19","author":"Fitchett","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012115053475900_ehf212528-bib-0007","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10557-017-6729-y","article-title":"The role of SGLT-2 inhibitors as part of optimal medical therapy in improving cardiovascular outcomes in patients with diabetes and coronary artery disease","volume":"31","author":"Mosleh","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026012115053475900_ehf212528-bib-0008","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European guidelines on cardiovascular disease prevention in clinical practice","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012115053475900_ehf212528-bib-0009","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1161\/CIRCULATIONAHA.115.014281","article-title":"Medication initiation burden required to comply with heart failure guideline recommendations and hospital quality measures","volume":"132","author":"Allen","year":"2015","journal-title":"Circulation"},{"key":"2026012115053475900_ehf212528-bib-0010","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S2213-8587(16)00049-8","article-title":"Heart failure event definitions in drug trials in patients with type 2 diabetes","volume":"4","author":"Sharma","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026012115053475900_ehf212528-bib-0011"},{"key":"2026012115053475900_ehf212528-bib-0012"},{"key":"2026012115053475900_ehf212528-bib-0013","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/ejhf.1223","article-title":"Multi-ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF-ACTION trial and ASIAN-HF registry","volume":"20","author":"Cooper","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115053475900_ehf212528-bib-0014","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.12528","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.12528","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/7\/1\/275\/65804313\/eschf_7_1_275.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/7\/1\/275\/65804313\/eschf_7_1_275.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:06:40Z","timestamp":1769026000000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/7\/1\/275\/8373149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,20]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,11,20]]},"published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.12528","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2]]},"published":{"date-parts":[[2019,11,20]]},"assertion":[{"value":"2019-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}